Ikarian Capital’s Definium Therapeutics DFTX Stock Holding History

Ikarian Capital’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.11M	Hold	58,803	–	–	0.09%	111
2025 Q4	$787K	Sell	58,803 -3,888	-6%	-$48.1K	0.06%	131
2025 Q3	$739K	Hold	62,691	–	–	0.07%	128
2025 Q2	$407K	Hold	62,691	–	–	0.08%	95
2025 Q1	$367K	Hold	62,691	–	–	0.05%	123
2024 Q4	$436K	Buy	62,691 +210	+0.3%	+$1.45K	0.06%	132
2024 Q3	$356K	Sell	62,481 -100,000	-62%	-$696K	0.05%	123
2024 Q2	$1.17M	Sell	162,481 -135,000	-45%	-$1.18M	0.2%	69
2024 Q1	$2.8M	Sell	297,481 -302,519	-50%	-$1.72M	0.31%	75
2023 Q4	$2.2M	Buy	+600,000	New	+$1.81M	0.21%	83
2022 Q3	–	Sell	-7,064	Closed	-$68K	–	143
2022 Q2	$68K	Hold	7,064	–	–	0.01%	133
2022 Q1	$118K	Buy	7,064 +397	+6%	+$6.89K	0.02%	178
2021 Q4	$138K	Buy	+6,667	New	+$213K	0.02%	166

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ikarian Capital's DFTX Position: Q1 2026 in Review

Ikarian Capital held its Definium Therapeutics (DFTX) position steady in Q1 2026 at 58,803 shares worth $1.11M. The position accounts for 0.09% of the portfolio, ranked #111.

Ikarian Capital first reported a position in DFTX in Q4 2021 and has held it in 13 quarters since. The position peaked at $2.8M in Q1 2024. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

Ikarian Capital held 58,803 shares of Definium Therapeutics worth $1.11M as of Q1 2026.
Ikarian Capital left its Definium Therapeutics share count unchanged in Q1 2026.
Definium Therapeutics made up 0.09% of Ikarian Capital's portfolio in Q1 2026, its #111 holding.
Ikarian Capital first reported a position in Definium Therapeutics in Q4 2021 and has held it in 13 quarters since.
Ikarian Capital's Definium Therapeutics position peaked at $2.8M in Q1 2024.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.